328233-13-2

Basic information

• Product Name: trans-7'-Oxo-spiro[cyclohexane-1,5'(7'H)-furo[3,4-b]pyridine]-4-carboxylic acid
• Synonyms: TRANS-7''-OXO-SPIRO[CYCLOHEXANE-1,5''(7''H)-FURO[3,4-B]PYRIDINE]-4-CARBOXYLIC ACID
• CAS NO: 328233-13-2
• Molecular Formula: C₁₃H₁₃NO₄
• Molecular Weight: 247.249
• Mol File: 328233-13-2.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 538.704 °C at 760 mmHg
• Flash Point: 279.598 °C
• Appearance: /
• Density: 1.41
• PKA: 4.51±0.20(Predicted)
• CAS DataBase Reference: trans-7'-Oxo-spiro[cyclohexane-1,5'(7'H)-furo[3,4-b]pyridine]-4-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: trans-7'-Oxo-spiro[cyclohexane-1,5'(7'H)-furo[3,4-b]pyridine]-4-carboxylic acid(328233-13-2)
• EPA Substance Registry System: trans-7'-Oxo-spiro[cyclohexane-1,5'(7'H)-furo[3,4-b]pyridine]-4-carboxylic acid(328233-13-2)

Safety Data

• Hazardous Substances Data: 328233-13-2(Hazardous Substances Data)

Usage

General Description

Trans-7'-Oxo-spiro[cyclohexane-1,5'(7'H)-furo[3,4-b]pyridine]-4-carboxylic acid is a chemical compound with a complex structure consisting of a cyclohexane ring fused with a furo[3,4-b]pyridine ring, and a carboxylic acid functional group attached at the 4-position. trans-7'-Oxo-spiro[cyclohexane-1,5'(7'H)-furo[3,4-b]pyridine]-4-carboxylic acid is a spirocyclic derivative, meaning that it contains two rings that share a single atom. It has potential pharmacological activities and may be used in medicinal chemistry research. The unique structure of this compound makes it an interesting target for synthetic organic chemists and pharmaceutical researchers exploring new drug candidates.

Upstream product

• 328233-12-1 trans-3-oxo-3H-spiro[4-aza-2-benzofuran-1,1'-cyclohexane]-4'-carbonitrile 

Downstream Products

• 328232-90-2 trans-3-oxo-N-(1-phenyl-1H-pyrazol-3-yl)-3H-spiro[4-aza-2-benzofuran-1,1'-cyclohexane]-4'-carboxamide 
• 328232-91-3 trans-3-oxo-N-(1-phenyl-1H-pyrazol-4-yl)-3H-spiro[4-aza-2-benzofuran-1,1'-cyclohexane]-4'-carboxamide 
• 328232-54-8 trans-3-oxo-N-(5-phenylpyrimidin-2-yl)-3H-spiro[4-aza-2-benzofuran-1,1'-cyclohexane]-4'-carboxamide 
• 1195313-58-6 trans-3-oxo-N-(5-phenylisoxazol-3-yl)-3H-spiro[4-aza-2-benzofuran-1,1'-cyclohexane]-4'-carboxamide 
• 1195313-59-7 trans-3-oxo-N-(3-phenyl-1H-pyrazol-5-yl)-3H-spiro[4-aza-2-benzofuran-1,1'-cyclohexane]-4'-carboxamide 
• 328232-52-6 trans-3-oxo-N-(5-phenylpyrazin-2-yl)-3H-spiro[4-aza-2-benzofuran-1,1'-cyclohexane]-4'-carboxamide 
• 1192312-52-9 C₂₃H₁₉FN₄O₃ 
• 1192312-55-2 C₂₄H₂₁FN₄O₃ 
• 1192312-54-1 C₂₄H₂₁FN₄O₄ 
• 1192312-53-0 C₂₄H₂₁FN₄O₄ 
• 1192312-51-8 C₂₃H₁₉FN₄O₃ 
• 1192312-50-7 C₂₃H₁₉FN₄O₃ 

Relevant articles and documents

Discovery of trans-N-[1-(2-fluorophenyl)-3-pyrazolyl]-3-oxospiro[6-azaisobenzofuran-1(3H),1′-cyclohexane]-4′-carboxamide, a potent and orally active neuropeptide Y Y5 receptor antagonist

A series of trans-3-oxospiro[(aza)isobenzofuran-1(3H),1′-cyclohexane]-4′-carboxamide derivatives were synthesized to identify potent NPY Y5 receptor antagonists. Of the compounds, 21j showed high Y5 binding affinity, metabolic stability and brain and cerebrospinal fluid (CSF) penetration, and low susceptibility to P-glycoprotein transporters. Oral administration of 21j significantly inhibited the Y5 agonist-induced food intake in rats with a minimum effective dose of 1 mg/kg. This compound was selected for proof-of-concept studies in human clinical trials.